We are live on
!
Find out more
EGI
EAM Global Investors Portfolio holdings
AUM
$47.1M
1-Year Est. Return
320.45%
This Fund
S&P 500
This Quarter
Est. Return
+30.7%
1 Year Est. Return
+320.45%
3 Year Est. Return
+2,492.23%
5 Year Est. Return
+19,933.92%
10 Year Est. Return
–
AUM
$356M
AUM Growth
-$31.2M
(-8.1%)
Cap. Flow
-$69.9M
Cap. Flow
% of AUM
-19.65%
Top 10 Holdings %
Top 10 Hldgs %
18.36%
Holding
216
New
41
Increased
27
Reduced
12
Closed
135
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perion Network
PERI
|
+$5.36M |
| 2 |
Transocean
RIG
|
+$4.94M |
| 3 |
Wynn Resorts
WYNN
|
+$4.85M |
| 4 |
Lincoln Electric
LECO
|
+$4.8M |
| 5 |
ATI
ATI
|
+$4.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Xenon Pharmaceuticals
XENE
|
+$5.77M |
| 2 |
ERF
Enerplus Corporation
ERF
|
+$4.93M |
| 3 |
Digi International
DGII
|
+$4.8M |
| 4 |
Extreme Networks
EXTR
|
+$4.71M |
| 5 |
MGP Ingredients
MGPI
|
+$4.59M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 30.49% |
| 2 | Technology | 24.32% |
| 3 | Consumer Discretionary | 15.04% |
| 4 | Healthcare | 15% |
| 5 | Financials | 5.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Viridian Therapeutics
VRDN
$2.61B
| $3.13M | 0.88% |
122,864
-29,042
| -19% | -$931K |
|
77
Prothena Corp
PRTA
$468M
| $3.06M | 0.86% |
63,120
-13,533
| -18% | -$715K |
|
78
Huron Consulting
HURN
$2.42B
| $2.94M | 0.83% |
36,547
-20,672
| -36% | -$1.5M |
|
79
Madrigal Pharmaceuticals
MDGL
$11.9B
| $2.79M | 0.78% |
11,510
+5,874
| +104% | +$1.6M |
|
80
Celldex Therapeutics
CLDX
$3.37B
| $2.27M | 0.64% |
63,143
-8,911
| -12% | -$385K |
|
81
Viemed Healthcare
VMD
$355M
| $984K | 0.28% |
101,882
-285,968
| -74% | -$2.49M |
|
82
Acadia Healthcare
ACHC
$2.96B
| – | – |
-36,224
| Closed | -$2.98M |
|
|
ACLX
83
DELISTED
Arcellx
ACLX
| – | – |
-78,433
| Closed | -$2.43M |
|
84
ADMA Biologics
ADMA
$2.18B
| – | – |
-836,323
| Closed | -$3.24M |
|
85
Addus HomeCare
ADUS
$2.23B
| – | – |
-15,945
| Closed | -$1.59M |
|
86
Aehr Test Systems
AEHR
$3.46B
| – | – |
-70,565
| Closed | -$1.42M |
|
87
American Eagle Outfitters
AEO
$3.07B
| – | – |
-101,561
| Closed | -$1.42M |
|
88
Albany International
AIN
$1.73B
| – | – |
-36,003
| Closed | -$3.55M |
|
|
AKRO
89
DELISTED
Akero Therapeutics
AKRO
| – | – |
-33,509
| Closed | -$1.84M |
|
90
Amalgamated Financial
AMAL
$1.48B
| – | – |
-55,187
| Closed | -$1.27M |
|
91
Amylyx Pharmaceuticals
AMLX
$2.53B
| – | – |
-45,750
| Closed | -$1.69M |
|
92
Amplify Energy
AMPY
$172M
| – | – |
-152,719
| Closed | -$1.34M |
|
93
Ardmore Shipping
ASC
$670M
| – | – |
-77,954
| Closed | -$1.12M |
|
94
A10 Networks
ATEN
$2.06B
| – | – |
-142,147
| Closed | -$2.36M |
|
95
Actinium Pharmaceuticals
ATNM
$24.2M
| – | – |
-115,387
| Closed | -$1.23M |
|
96
Axsome Therapeutics
AXSM
$11.4B
| – | – |
-21,288
| Closed | -$1.64M |
|
97
Banner Corp
BANR
$2.43B
| – | – |
-48,541
| Closed | -$3.07M |
|
98
Barrett Business Services
BBSI
$783M
| – | – |
-95,508
| Closed | -$2.23M |
|
99
Build-A-Bear
BBW
$467M
| – | – |
-77,369
| Closed | -$1.84M |
|
|
BELFB
100
Bel Fuse Inc Class B
BELFB
$4.1B
| – | – |
-48,324
| Closed | -$1.59M |
|
Similar funds
IPHI
FCM
RRC
MCMC
CM
PCM
CCG
CT
EAM Global Investors's Q1 2023 Portfolio in Review
As of Q1 2023, EAM Global Investors held 216 positions worth $356M, down 8.1% from $387M the previous quarter. Its ten largest holdings account for 18% of the portfolio.
EAM Global Investors withdrew a net $69.9M in Q1 2023, closing 135 positions and reducing 12 holdings. Its most notable exit was Xenon Pharmaceuticals, an estimated $5.77M position sold in full.
By sector, the portfolio is most concentrated in Industrials at 30% of assets, up from 15% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, EAM Global Investors opened a new position in Perion Network worth $6.38M.
- EAM Global Investors's largest Q1 2023 buy was Perion Network: 161,132 shares worth $6.38M.
- EAM Global Investors added most to Iridium Communications in Q1 2023, an estimated $3.46M increase.
- EAM Global Investors's biggest Q1 2023 reduction was Viemed Healthcare, cutting an estimated $2.49M.
- EAM Global Investors fully exited Xenon Pharmaceuticals in Q1 2023, selling an estimated $5.77M.
- EAM Global Investors's ten largest holdings make up 18% of its $356M portfolio in Q1 2023.
- EAM Global Investors opened 41 new positions and closed 135 in Q1 2023.
- EAM Global Investors's portfolio value fell 8.1% quarter-over-quarter to $356M.
Based on EAM Global Investors's 13F filing for Q1 2023, filed 15 May 2023.